FBLG

0.705015.06%
RE

Robert E. Hoffman

CEO & Principal Accounting Officer

Mr. Robert E. Hoffman, BBA, CPA, is CEO and principal accounting officer of CytoDyn Inc. from October 20, 2026 and had been Chief Financial Officer of CytoDyn Inc. since May 15, 2025 until October 2026 and its Independent Director since May 14, 2025. He served as an Independent Director at FibroBiologics, Inc. (Formerly, FibroBiologics LLC) since April 2021 until October 30, 2024 and also served as Director since October 30, 2024 and had been its Interim CFO since October 30, 2024 until May 14, 2025. Mr. Hoffman was Independent Director of Esperion Therapeutics, Inc. from April 1, 2025 to July 13, 2026. He had been Independent Director of Antibe Therapeutics Inc. since November 15, 2020 until April 2024 and had been its Chair of the Board since 2023. He served as a Director of Saniona AB (publ) from May 26, 2021 to May 2022. He is Director of Tuhura Biosciences, Inc (formerly known as Morphogenesis, Inc). October 18, 2024. He was Chairman of the Board at Kintara Therapeutics, Inc. since June 2, 2018 until 2024 and also served as its Interim Chief Financial Officer since June 01, 2023 until 2024 and Chief Executive Officer and President since November 08, 2021 until 2024. He was Chief Financial Officer of Kintara Therapeutics, Inc. Mr. Hoffman served as a Director of Aravive, Inc. from October 12, 2018 to April 08, 2020. He served as Chief Financial Officer and Senior Vice President of Finance at Heron Therapeutics, Inc. since joining in April 24, 2017 until October 2020. He has been a Director at Kintara Therapeutics, Inc. since April 11, 2018. He joined the Kintara Therapeutics, Inc. in April 11, 2018. He served as the Chief Financial Officer and Executive Vice President of Innovus Pharmaceuticals, Inc. from September 2016 to April 21, 2017 and served as its Principal Accounting Officer from September 6, 2016 to April 21, 2017. Mr. Hoffman served as the Chief Financial Officer of AnaptysBio, Inc. from July 13, 2015 to September 2016. Mr. Hoffman served as the Senior Vice President of Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. from June 2012 to July 10, 2015 and served as its Principal Accounting Officer from June 15, 2012 to July 10, 2015. He served as the Chief Financial Officer at Polaris Pharmaceuticals, Inc. since joining in March 2011 until August 2011. He served as the Chief Financial Officer of Arena Pharmaceuticals Inc. and Vice President of Finance from August 2011 to June 2012 and from December 2005 to March 2011. He served as Chief Accounting Officer of Arena Pharmaceuticals from June 2004 to December 2005 and served as its Controller from August 1997 to April 2000. He served as the Chief Financial Officer of ChemNavigator and as Vice President of Finance of BRL Screening. From 1994 to 1997, he served as an Assistant Controller of Document Sciences Corporation. Mr. Hoffman served as the President of the San Diego Chapter of Financial Executives International. He served as an Independent Director of CombiMatrix Corporation from July 17, 2013 to November 14, 2017. He was part of the founding management team of Arena Pharmaceuticals, Inc. in 1997. He served as a Member of Advisory Board at Innovus Pharmaceuticals, Inc. from 2013 to April 21, 2017 and served as its Member of Business & Finance Advisory Board since June 27, 2013. He had been an Independent Director of ASLAN Pharmaceuticals Limited since October 30, 2018 and ASLAN Pharmaceuticals Pte. Ltd. since December 2018. He is a member of the board of directors of FibroGenesis, since April 2021. He served as an Independent Director at Kura Oncology, Inc. from March 2015 to August 3, 2021. He was an advisor to the Financial Accounting Standard Board (FASB) from 2010 to 2020 advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman is also a founding Board Member of Day for Change. He was a Director of the San Diego Chapter of Financial Executives International. Mr. Hoffman is also a Member of the San Diego Chapter of Financial Executives International. He is a Member of the Association of Bioscience Financial Officers and a Member of the Board of Directors of the San Diego County Credit Union. He served as an Independent Director of MabVax Therapeutics Holdings, Inc. since September 2014 June 12, 2017. Mr. Hoffman served as Consultant of MabVax Therapeutics Holdings, Inc. He is licensed as a Certified Public Accountant (inactive) in the State of California. He is Financial Expert. Mr. Hoffman holds a B. B.A. from St. Bonaventure University.

Positions